• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CXCR4 拮抗剂 EPI-X4 从人血白蛋白制剂中缺失。

Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations.

机构信息

Institute of Molecular Virology, Ulm University Medical Center, 89081, Ulm, Germany.

German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen, Institute Frankfurt, 60528, Frankfurt, Germany.

出版信息

J Transl Med. 2021 May 3;19(1):190. doi: 10.1186/s12967-021-02859-6.

DOI:10.1186/s12967-021-02859-6
PMID:33941197
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8094565/
Abstract

BACKGROUND

Endogenous Peptide Inhibitor of CXCR4 (EPI-X4) is a natural antagonist of the CXC chemokine receptor 4 (CXCR4). EPI-X4 is a 16-mer peptide that is released from human serum albumin (HSA) by acidic aspartic proteases such as Cathepsin D and E. Since human serum albumin (HSA) is an important medicinal substance we asked whether different pharmaceutical HSA products contain EPI-X4 which could have been generated during manufacturing and whether HSA can serve as a substrate for cathepsins despite of the presence of stabilizers like caprylate.

METHODS

Eight pharmaceutical HSA preparations representing all currently used fractionation technologies were analyzed. The previously described specific EPI-X4 ELISA was used for quantification; in vitro EPI-X4 generation by acidification in the presence or absence of cathepsins was followed by quantification with ELISA.

RESULTS

None of the pharmaceutical HSA preparations tested contained EPI-X4. Acidification of HSA did not generate EPI-X4. Addition of cathepsins D and E to acidified HSA yielded high concentrations of EPI-X4 in all HSA preparations, indistinguishable between individual products.

CONCLUSION

Medicinal HSA preparations per se do not contain EPI-X4, but will replenish its precursor which can be cleaved to EPI-X4 in vivo, environmental conditions permitting.

摘要

背景

内源性 CXCR4 趋化因子受体(EPI-X4)抑制剂是 CXC 趋化因子受体 4(CXCR4)的天然拮抗剂。EPI-X4 是一种 16 肽,可通过酸性天冬氨酸蛋白酶(如组织蛋白酶 D 和 E)从人血清白蛋白(HSA)中释放出来。由于人血清白蛋白(HSA)是一种重要的药用物质,我们询问了不同的药用 HSA 产品是否含有在制造过程中产生的 EPI-X4,以及 HSA 是否可以作为组织蛋白酶的底物,尽管存在稳定剂如辛酸。

方法

分析了代表所有当前使用的分级技术的八种药用 HSA 制剂。使用先前描述的特异性 EPI-X4 ELISA 进行定量;通过在存在或不存在组织蛋白酶的情况下酸化来进行体外 EPI-X4 生成,并通过 ELISA 进行定量。

结果

测试的八种药用 HSA 制剂均未含有 EPI-X4。HSA 的酸化没有产生 EPI-X4。将组织蛋白酶 D 和 E 添加到酸化的 HSA 中,在所有 HSA 制剂中产生了高浓度的 EPI-X4,在各个产品之间没有区别。

结论

药用 HSA 制剂本身不含 EPI-X4,但在环境条件允许的情况下,会补充其前体,可在体内被切割为 EPI-X4。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acb7/8094565/18e4d87b69be/12967_2021_2859_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acb7/8094565/18e4d87b69be/12967_2021_2859_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acb7/8094565/18e4d87b69be/12967_2021_2859_Fig1_HTML.jpg

相似文献

1
Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations.CXCR4 拮抗剂 EPI-X4 从人血白蛋白制剂中缺失。
J Transl Med. 2021 May 3;19(1):190. doi: 10.1186/s12967-021-02859-6.
2
EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models.EPI-X4,一种 CXCR4 拮抗剂,可抑制胰腺癌和淋巴瘤模型中的肿瘤生长。
Peptides. 2024 May;175:171111. doi: 10.1016/j.peptides.2023.171111. Epub 2023 Nov 28.
3
Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability.高级 EPI-X4 衍生物与人血清白蛋白发生共价结合,从而导致其血浆稳定性延长。
Int J Mol Sci. 2022 Nov 30;23(23):15029. doi: 10.3390/ijms232315029.
4
Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists.计算建模和 EPI-X4/CXCR4 复合物的实验验证,使小分子肽拮抗剂的合理设计成为可能。
Commun Biol. 2021 Sep 22;4(1):1113. doi: 10.1038/s42003-021-02638-5.
5
Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability.开发 N 端修饰的 CXCR4 拮抗肽 EPI-X4 变体,以增强其血浆稳定性。
J Med Chem. 2023 Nov 23;66(22):15189-15204. doi: 10.1021/acs.jmedchem.3c01128. Epub 2023 Nov 8.
6
An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation.一种内源性CXCR4拮抗剂的优化衍生物可预防特应性皮炎和气道炎症。
Acta Pharm Sin B. 2021 Sep;11(9):2694-2708. doi: 10.1016/j.apsb.2020.12.005. Epub 2020 Dec 13.
7
Conformational States of the CXCR4 Inhibitor Peptide EPI-X4-A Theoretical Analysis.CXCR4 抑制剂肽 EPI-X4-A 的构象态:理论分析。
Int J Mol Sci. 2023 Nov 12;24(22):16229. doi: 10.3390/ijms242216229.
8
Discovery and characterization of an endogenous CXCR4 antagonist.发现并鉴定一种内源性 CXCR4 拮抗剂。
Cell Rep. 2015 May 5;11(5):737-47. doi: 10.1016/j.celrep.2015.03.061. Epub 2015 Apr 23.
9
Fatty acid conjugated EPI-X4 derivatives with increased activity and in vivo stability.具有增强的活性和体内稳定性的脂肪酸共轭 EPI-X4 衍生物。
J Control Release. 2024 Sep;373:583-598. doi: 10.1016/j.jconrel.2024.07.049. Epub 2024 Jul 30.
10
Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4.人血清白蛋白的蛋白水解加工产生EPI-X4,一种CXCR4的内源性拮抗剂。
J Leukoc Biol. 2016 Jun;99(6):863-8. doi: 10.1189/jlb.2MR1115-521RR. Epub 2016 Mar 10.

引用本文的文献

1
Conformational States of the CXCR4 Inhibitor Peptide EPI-X4-A Theoretical Analysis.CXCR4 抑制剂肽 EPI-X4-A 的构象态:理论分析。
Int J Mol Sci. 2023 Nov 12;24(22):16229. doi: 10.3390/ijms242216229.

本文引用的文献

1
An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation.一种内源性CXCR4拮抗剂的优化衍生物可预防特应性皮炎和气道炎症。
Acta Pharm Sin B. 2021 Sep;11(9):2694-2708. doi: 10.1016/j.apsb.2020.12.005. Epub 2020 Dec 13.
2
Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia.天然存在的CXCR4拮抗剂EPI-X4对华氏巨球蛋白血症中CXCR4的靶向作用
Cancers (Basel). 2021 Feb 16;13(4):826. doi: 10.3390/cancers13040826.
3
Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands.
基于微量滴定板的抗体竞争分析测定 CXCR4 配体的结合亲和力和血浆/血液稳定性。
Sci Rep. 2020 Sep 29;10(1):16036. doi: 10.1038/s41598-020-73012-4.
4
Albumin Modifies Responses to Hematopoietic Stem Cell Mobilizing Agents in Mice.白蛋白修饰小鼠造血干细胞动员剂的反应。
Cells. 2019 Dec 18;9(1):4. doi: 10.3390/cells9010004.
5
Involvement of CXCR4 in Normal and Abnormal Development.CXCR4 在正常和异常发育中的作用。
Cells. 2019 Feb 20;8(2):185. doi: 10.3390/cells8020185.
6
Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.莫泽比利(普乐沙福,AMD3100),在美国食品药品监督管理局批准其上市十年后。
Antivir Chem Chemother. 2019 Jan-Dec;27:2040206619829382. doi: 10.1177/2040206619829382.
7
Removal of stabilizers from human serum albumin by adsorbents and dialysis used in blood purification.通过血液净化中使用的吸附剂和透析从人血清白蛋白中去除稳定剂。
PLoS One. 2018 Jan 24;13(1):e0191741. doi: 10.1371/journal.pone.0191741. eCollection 2018.
8
Overview of Albumin and Its Purification Methods.白蛋白及其纯化方法概述。
Adv Pharm Bull. 2016 Dec;6(4):495-507. doi: 10.15171/apb.2016.063. Epub 2016 Dec 22.
9
Evaluation of EPI-X4 as a urinary peptide biomarker for diagnosis and prognosis of late acute GvHD.评估EPI-X4作为晚期急性移植物抗宿主病诊断和预后的尿肽生物标志物。
Bone Marrow Transplant. 2016 Aug;51(8):1137-9. doi: 10.1038/bmt.2016.65. Epub 2016 Apr 4.
10
Proteolytic processing of human serum albumin generates EPI-X4, an endogenous antagonist of CXCR4.人血清白蛋白的蛋白水解加工产生EPI-X4,一种CXCR4的内源性拮抗剂。
J Leukoc Biol. 2016 Jun;99(6):863-8. doi: 10.1189/jlb.2MR1115-521RR. Epub 2016 Mar 10.